An Evidence-Based Guide to LDN, Ketotifen, and Integrative Therapies

Updated Edition — October 2026

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

About Dr. Kim

Yoon Hang Kim, MD, MPH, is board-certified in Preventive Medicine with more than 20 years of clinical experience. A University of Arizona/Andrew Weil Center for Integrative Medicine fellowship-trained physician, he holds certifications in preventive medicine, medical acupuncture, and integrative and functional medicine. Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity.

He is the author of eight books — including MCAS: Epidemic in Plain Sight, LDN Primer, LDN for Clinicians, and Integrative Oncology: Evidence-Based Strategies to Support Cancer Treatment — and more than 25 peer-reviewed articles. He is the founder of the LDN Support Group.

Professional: www.yoonhangkim.com |

Clinical: www.directintegrativecare.com |

Blog: www.ifmsynergy.com

Mast Cell Activation Syndrome (MCAS) is a complex and often underdiagnosed condition in which mast cells — an essential part of the immune system — become dysregulated and release mediators like histamine, prostaglandins, and cytokines inappropriately. This can result in a wide array of symptoms ranging from fatigue and brain fog to skin reactions, gastrointestinal issues, and even anaphylaxis-like responses.

While conventional medicine typically focuses on antihistamines and mast cell stabilizers, functional medicine seeks to address the root causes and restore balance to the immune system. This approach is increasingly supported by clinical evidence and utilized by MCAS specialists including Dr. Lawrence Afrin, Dr. Tania Dempsey, and Dr. Leonard Weinstock.

Below are key tools used in a functional medicine approach to MCAS: Low Dose Naltrexone (LDN), Ketotifen, Cromolyn Sodium, an Anti-Inflammatory Diet, Amlexanox, and Rapamycin.

1. Low Dose Naltrexone (LDN): Calming the Overactive Immune Response

Low Dose Naltrexone (LDN) is a compounded medication that works by transiently blocking opioid receptors, which paradoxically results in an upregulation of the body's natural endorphins and enkephalins. These molecules don't just influence mood and pain — they also have immunomodulatory effects.

In MCAS, where the immune system is inappropriately reactive, LDN appears to help through several mechanisms:

• TLR4 Inhibition: LDN blocks Toll-like receptor 4, dampening the NF-κB inflammatory pathway

• Reducing Pro-inflammatory Cytokines: Decreases IL-6 and TNF-α while increasing regulatory cytokines like IL-10

• Modulating T-cell Activity: T-cell microparticles activate mast cells; LDN reduces excessive T-cell dysfunction

• Stabilizing Mast Cells Indirectly: Through immune system recalibration rather than direct mast cell action

• Improving Resilience to Triggers: Better tolerance to stress, infection, or allergens

The Evidence

The landmark 2018 BMJ Case Report by Weinstock et al. documented a client with severe POTS and MCAS who achieved a 43% decrease in MCAS severity with LDN combined with IVIg therapy. Data from the LDN Research Trust involving 116 MCAS clients showed that 60% reported improvements in various symptoms. A 2025 study published in ScienceDirect found MCAS clients rated LDN benefit at 5.6/10 mean score for overall health status.

LDN is not a cure, but many clients report significant improvement in fatigue, brain fog, and inflammatory symptoms over time. Doses typically range from 0.5 mg to 4.5 mg, individualized to client tolerance. The "rebound" effect is primarily why it is dosed nightly.

2. Ketotifen: Stabilizing the Mast Cells

Ketotifen is a powerful mast cell stabilizer and H1 antihistamine, typically available through compounding pharmacies in the U.S. Unlike common over-the-counter antihistamines, ketotifen has dual action:

• Prevents Mast Cell Degranulation: Reduces the release of histamine, tryptase, and various prostaglandins by stabilizing calcium permeability in mast cell membranes

• Blocks Histamine Receptors: Reduces downstream symptoms like flushing, hives, or gastrointestinal distress

In functional medicine, ketotifen is often used as a bridge therapy to help control symptoms while deeper root causes — like gut dysbiosis, mold exposure, or chronic infections — are addressed. It is preferred for systemic, skin, and respiratory symptoms due to its H1-receptor antagonism.

Common starting doses are 0.5–1 mg at bedtime, with titration based on response and side effects. Some clients may experience drowsiness initially. Maximum therapeutic effect typically requires 6–12 weeks of consistent use.

3. Cromolyn Sodium: The GI Specialist

Cromolyn sodium is the gold standard for GI-dominant MCAS symptoms because of its negligible systemic absorption (<1%). It works by inhibiting both immediate and late-phase mast cell mediator release.

Unlike ketotifen, cromolyn doesn't have antihistamine properties — it is purely a mast cell stabilizer. This makes it particularly effective for abdominal pain, nausea, bloating, diarrhea, and food-related reactions.

Cromolyn is available as an oral solution (Gastrocrom®) or can be compounded into capsules for individuals sensitive to liquid formulations.

4. Anti-Inflammatory Diet: Lowering the Baseline Fire

Food is medicine — or it's fuel for the fire. An anti-inflammatory diet is foundational in managing MCAS. Because mast cell activation can be triggered by inflammatory foods and gut permeability (leaky gut), removing dietary triggers is crucial.

Core Principles

• Eliminate High-Histamine Foods: Fermented foods, aged cheeses, alcohol, and leftovers can exacerbate symptoms

• Avoid Common Allergens: Gluten, dairy, soy, and artificial additives can be mast cell irritants

• Focus on Whole, Nutrient-Dense Foods: Fresh, organic vegetables and fruits (especially low-histamine options like blueberries, zucchini, and leafy greens); wild-caught fish rich in omega-3s; healthy fats (olive oil, avocado, coconut oil); clean protein (pasture-raised meats, collagen peptides)

Supportive Supplements

Quercetin: A bioflavonoid that inhibits the release of histamine, tryptase, and pro-inflammatory cytokines from mast cells. While most mechanistic studies are preclinical, clinical use is widespread due to its favorable safety profile. Typical doses range from 500–1,000 mg daily.

Vitamin C: Enhances Diamine Oxidase (DAO) enzyme activity and has been shown to decrease circulating histamine levels. Typical doses range from 500–2,000 mg daily.

DAO Enzymes: Support histamine breakdown from dietary sources. Most effective supplements are derived from pig kidney extract. Taken before meals containing histamine.

5. Amlexanox: An Emerging Immunomodulator for Mast Cell Dysregulation

Amlexanox is a small-molecule compound with a decades-long safety record that is now drawing serious interest in the MCAS and functional immunology space. It has been FDA-approved in the U.S. as a topical paste (Aphthasol) for recurrent aphthous ulcers since 1996, and has been used in Japan for decades as an oral agent for asthma, allergic rhinitis, and stomatitis — giving it an unusually deep human safety database relative to most emerging immune-modulating agents.

Mechanism of Action: TBK1 and IKKε Inhibition

Amlexanox's primary pharmacological target is selective inhibition of two non-canonical IκB kinases: Tank-Binding Kinase 1 (TBK1) and IκB kinase epsilon (IKKε). This mechanism matters deeply in MCAS for several reasons:

• TBK1/IKKε Drive Innate Immune Amplification: These kinases sit downstream of pattern recognition receptors — including TLR3, TLR4, STING, and RIG-I — that are frequently activated in MCAS-associated conditions like Long COVID, mold illness, and chronic Lyme. By selectively inhibiting TBK1/IKKε, amlexanox dampens the innate immune signaling cascade without broadly suppressing immunity.

• Type I Interferon Reduction: TBK1/IKKε are essential drivers of type I interferon (IFN-α/β) production. Dysregulated type I IFN signaling has been implicated in MCAS-associated neuroinflammation, post-viral fatigue states, and Long COVID. Amlexanox reduces type I IFN production from peripheral blood mononuclear cells stimulated through both endosomal and cytosolic pathways.

• B Cell and Autoimmune Modulation: A 2025 study demonstrated that amlexanox inhibits spontaneous MX1 expression in PBMCs from individuals with systemic lupus erythematosus (SLE), primary Sjögren's disease, and systemic sclerosis, and suppresses B cell differentiation into plasmablasts and plasma cells — suggesting potential utility across the autoimmune-MCAS overlap population.

• NF-κB Pathway Modulation: Amlexanox also inhibits IKKε-mediated NF-κB activation, reducing downstream pro-inflammatory cytokine production (TNF-α, IL-6) that drives mast cell priming.

• Mast Cell Relevance: While direct mast-cell-stabilizing trials are limited, the upstream innate immune and interferon pathways that amlexanox targets are known drivers of mast cell sensitization and lowered activation thresholds. Its mechanism is therefore complementary — rather than redundant — to existing mast cell stabilizers.

Safety Profile and Longevity Medicine Context

Amlexanox's oral safety record from Japan is particularly compelling. Decades of use at anti-asthmatic and anti-allergic doses (typically 10–50 mg orally, multiple times daily) have not produced the serious adverse event profile seen with broad immunosuppressants. This positions it favorably for clients with complex MCAS who are often extraordinarily sensitive to new medications and prone to adverse drug reactions.

Preclinical and early clinical research has also shown amlexanox to have favorable metabolic effects — improving insulin sensitivity and reducing obesity-associated inflammation — which is directly relevant to MCAS clients with concurrent metabolic dysfunction, a common phenotype.

Current Status and Clinical Positioning

Amlexanox is not yet FDA-approved for systemic MCAS or autoimmune indications in the U.S. Its use in MCAS is off-label and currently supported primarily by mechanistic rationale, preclinical data, and its established safety record in human populations. It is best positioned as an adjunct immunomodulator in:

• Neuroinflammatory MCAS with post-viral or interferon-driven features (Long COVID, CIRS)

• MCAS with concurrent autoimmune overlap (SLE, Sjögren's, systemic sclerosis)

• Refractory MCAS where upstream innate immune amplification appears to be the primary driver

Important: Amlexanox use in MCAS is off-label. It requires informed consent, individualized clinical judgment, and ongoing monitoring. Compounded oral formulations may be required in the U.S. for systemic dosing. For detailed mechanistic discussion, see Kim YH, "Mast Cell Activation Syndrome Book Chapter," IFM Synergy, 2026.

6. Rapamycin: mTOR Inhibition, Autophagy Restoration, and Cautious Promise

Rapamycin (sirolimus) has become one of the most discussed emerging agents in integrative and longevity medicine — not primarily because of MCAS-specific evidence, but because of its well-characterized mechanism targeting a pathway increasingly implicated in chronic inflammatory and post-viral conditions.

Background: From Transplant Medicine to Longevity Research

Rapamycin is an FDA-approved macrolide compound — approved for kidney transplant rejection prophylaxis and the rare lung disease lymphangioleiomyomatosis (LAM) — with a well-established, decades-long human safety database in immunological applications. In longevity medicine, rapamycin has become a cornerstone of mTOR research. Its ability to extend lifespan in multiple animal models, combined with acceptable safety at low intermittent doses in aging research protocols, has made it one of the most actively studied compounds in the longevity space. This safety track record at lower doses is a meaningful consideration when evaluating its potential in chronic inflammatory conditions.

Mechanism: mTOR Inhibition and Autophagy Restoration

Rapamycin selectively inhibits mTOR complex 1 (mTORC1), a master regulatory kinase that controls cellular growth, protein synthesis, immune activation, and — critically — autophagy. Autophagy is the cell's housekeeping system for clearing damaged proteins and dysfunctional organelles. When mTOR is constitutively overactive (as proposed in a subgroup of ME/CFS and potentially in some MCAS phenotypes), autophagy is suppressed, leading to accumulation of cellular debris, mitochondrial dysfunction, and amplified innate immune signaling.

In the MCAS context, the proposed pathway is:

mTOR overactivation → impaired autophagy → cellular stress and damaged protein accumulation → amplified innate immune signaling → lower mast cell activation threshold

Rapamycin's inhibition of mTORC1 promotes autophagic clearance, potentially reducing the cellular stress signals that prime mast cells for hyperreactivity.

The ME/CFS Signal and Relevance to MCAS

Two peer-reviewed open-label observational cohorts published in the Journal of Translational Medicine (2025 and 2026) reported meaningful improvement in client-reported fatigue, post-exertional malaise, and quality of life in ME/CFS clients receiving low-dose rapamycin over 90 days. Autophagy biomarker changes (decreased pSer258-ATG13, increased BECLIN-1) were directionally consistent with the proposed mechanism.

These findings are hypothesis-generating — neither study included a placebo group, so the drug's true effect cannot yet be separated from natural symptom fluctuation or expectation effects. A randomized, double-blind, placebo-controlled trial (RAPA STEP 4 ME & COVID) is planned for approximately 2027, which will be the genuine evidentiary test.

The ME/CFS overlap with MCAS is profound and well-documented. For clients with ME/CFS-MCAS overlap who have not responded adequately to conventional mast cell stabilization and LDN, the mTOR/autophagy hypothesis provides a biologically coherent rationale for consideration under close clinical supervision.

Safety Considerations at Low Doses

At the weekly low doses used in longevity and ME/CFS protocols (typically 1–6 mg/week generic sirolimus), the adverse event profile is considerably more favorable than at transplant immunosuppression doses. That said, meaningful risks persist and require explicit clinical attention:

• Aphthous stomatitis, dyslipidemia, mild immunosuppression, acneiform rash

• Drug interactions via CYP3A4 — particularly relevant: CBD and St. John's Wort (both common in the MCAS population) are listed in current prescribing information

• Reproductive safety: sirolimus carries fetal harm risk; contraceptive counseling is essential for women of childbearing potential

• Monitoring: CBC, metabolic panel, lipids, and periodic assessment of immunological status

Clinical Positioning

Rapamycin in MCAS is not a first-, second-, or even third-line agent. It is an emerging investigational option for consideration in:

• ME/CFS-MCAS overlap with significant post-exertional malaise unresponsive to standard protocols

• Refractory multi-system MCAS with features suggesting mTOR dysregulation or impaired cellular housekeeping

• Clients already engaged in longevity medicine protocols under physician supervision, where MCAS is a complicating condition

Important: Rapamycin use in MCAS is off-label and investigational. It requires thorough informed consent, drug-interaction review (particularly for CBD and serotonergic agents), reproductive safety counseling, structured laboratory monitoring, and honest communication that controlled proof of efficacy in MCAS does not yet exist. For the full evidence review, see Kim YH, "Rapamycin in ME/CFS: Promise, Proof, and the Path Forward," IFM Synergy, 2026.

Clinical Algorithm: Matching Treatment to Client Phenotype

Not all MCAS clients present the same way. The table below categorizes therapeutic agents by predominant symptom pattern, updated to incorporate amlexanox and rapamycin:

Final Thoughts

Managing MCAS requires more than simply suppressing symptoms. The functional medicine model offers a systems-based approach, aiming to rebalance the immune system, identify root triggers, and restore resilience.

The therapeutic landscape is evolving rapidly. The foundational tools — LDN, ketotifen, cromolyn, and an anti-inflammatory diet — continue to form the clinical backbone and have the broadest safety and observational evidence base. Two newer agents are now entering serious clinical consideration:

Amlexanox brings something rare in this space: a decades-long human safety record at therapeutic doses, built from its Japanese approval for asthma and allergic rhinitis and its U.S. FDA approval for aphthous ulcers. Its selective TBK1/IKKε inhibition targets the innate immune amplification that underlies many of the most refractory MCAS phenotypes — particularly those driven by Long COVID, mold illness, and autoimmune overlap. The mechanistic rationale is strong; MCAS-specific clinical trials are still needed.

Rapamycin offers a biologically coherent hypothesis for the ME/CFS-MCAS overlap population through mTOR inhibition and autophagy restoration. Two open-label observational cohorts published in 2025 and 2026 produced a signal worth taking seriously. That signal has not yet been confirmed in a placebo-controlled trial, and honest clinical practice requires communicating that uncertainty directly. For clients already in longevity medicine programs under close physician supervision, or those with refractory ME/CFS-MCAS overlap, the risk-benefit calculus may support cautious consideration — with full informed consent, drug-interaction screening (particularly for CBD and serotonergic agents), and reproductive safety counseling.

The 2025 MedCrave publication on LDN and hydroxycarbamide for mast cell disorders highlights the ongoing shift toward immunomodulatory combinations in this emerging field. Amlexanox and rapamycin represent the next frontier of that shift.

As always, work with a knowledgeable healthcare provider to tailor any treatment to your specific needs — especially when using compounded medications or navigating complex immune conditions.

References

Primary Clinical Trials & Case Reports

Bonamichi-Santos R, Castells M, Galvão L. Non-clonal mast cell activation: A growing body of evidence. Frontiers in Immunology. 2018;9:2373.

Molderings GJ, et al. Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg's Archives of Pharmacology. 2016;389(7):671–694.

Theoharides TC, Tsilioni I, Bawazeer M. Mast cells, neuroinflammation and pain in fibromyalgia syndrome. Frontiers in Cellular Neuroscience. 2019;13:353.

Weinstock LB, et al. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports. 2018;bcr-2017-221405.

Weinstock LB, Afrin LB. Use of low dose naltrexone and hydroxycarbamide for mast cell disorders (ISM, MCAS, HaT). Journal of Cancer Prevention & Current Research. 2025;16(1):12–15.

Rapamycin / mTOR Evidence

Ruan BT, et al. Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study. Journal of Translational Medicine. 2025;23(1):1148.

Gile B, et al. Association of rapamycin treatment with modulation of purine metabolism, reduced microglial inflammatory responses, improved mitochondrial energy metabolism, and alleviation of fatigue symptoms in ME/CFS subjects: Phase-II observational study. Journal of Translational Medicine. 2026;24:921.

Puente C, et al. Nutrient-regulated phosphorylation of ATG13 inhibits starvation-induced autophagy. Journal of Biological Chemistry. 2016;291(11):6026–6035.

Amlexanox Evidence

Gonzalez-Hilarion S, et al. Rescue of nonsense mutations by amlexanox in human cells. Orphanet Journal of Rare Diseases. 2012;7:58.

Homan KT, et al. Identification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor. Molecules. 2014;19(10):16937–16954.

Lindblom J, et al. Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseases. 2025.

Mechanistic & Expert Reviews

Afrin LB, Weinstock LB. Oral cromolyn sodium therapy for mast cell activation syndrome. American Journal of the Medical Sciences. 2014;347(6):500–502.

Dempsey T. Methylene blue: A look at its surprising health benefits and mast cell stabilization. Dr. Tania Dempsey Integrative Medicine. 2024.

Toljan K, Vrooman B. Low-dose naltrexone (LDN) — Review of therapeutic utilization. Medical Sciences. 2018;6(4):82.

Author's Related Work

Kim YH. Rapamycin in ME/CFS: Promise, proof, and the path forward. IFM Synergy. October 2026. https://www.ifmsynergy.com/rapamycin-in-me-cfs-promise-proof-and-the-path-forward/

Kim YH. Mast Cell Activation Syndrome Book Chapter. IFM Synergy. October 2026. https://www.ifmsynergy.com/mast-cell-activation-syndrome/

Yoon Hang Kim, MD, MPH is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and the founder of the LDN Support Group.

Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

Keywords: MCAS, Mast Cell Activation Syndrome, functional medicine, LDN, low dose naltrexone, ketotifen, cromolyn sodium, amlexanox, TBK1, rapamycin, mTOR, autophagy, mast cell stabilizer, histamine intolerance, anti-inflammatory diet, integrative medicine, POTS, dysautonomia, quercetin, DAO enzyme, ME/CFS, Long COVID